Senator Susan Collins (R-Maine) is currently navigating a political challenge regarding the confirmation of Dr. Heidi Overton, President Trump’s nominee to lead the Food and Drug Administration (FDA). As a moderate Republican who has historically positioned herself as an advocate for abortion rights, Collins’ vote is being closely monitored by interest groups and political observers alike.

The confirmation process is set to move forward with Dr. Overton scheduled to testify before the Senate Health, Education, Labor and Pensions (HELP) Committee this Thursday. The hearing is expected to focus on how the nominee might approach reproductive health policies and the regulation of medications related to abortion, such as mifepristone.

While the nomination process is standard, the focus on Collins highlights the internal tension within the Republican Party regarding reproductive health. Supporters of abortion access are looking to see if Collins will use her influence to block or demand concessions from a nominee whose views on reproductive rights may conflict with her own. Conversely, party leadership is looking for a smooth confirmation process to solidify the administration's health agenda. The outcome of this hearing will likely serve as a barometer for how the Senate will handle future appointments that intersect with sensitive social issues.